IAG . Bankinter Fija su Precio Objetivo en 3,50€ Por Acción . En Marcha la Recompra de Acciones .
07 diciembre 2009
ASH : Study Suggests Maintenance Role for Novel Factor Xa Inhibitor .
Results from a randomized, placebo-controlled trial in patients with a history of venous thromboembolic events suggest a benefit for maintenance therapy with rivaroxaban, an investigational oral selective Factor Xa inhibitor.
...
‹
›
Inicio
Ver versión web